Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01416688 · ClinicalTrials.gov registry record

S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride

A clinical trial of Lung Cancer and Colorectal Cancer, sponsored by SWOG Cancer Research Network.

Completed
Registry status
146
Enrollment target
20
Study locations

NCT01416688 is a study of Lung Cancer and Colorectal Cancer that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 146 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01416688, a study of Lung Cancer and Colorectal Cancer, has completed, sponsored by SWOG Cancer Research Network.

COMPLETED
Registry status
146 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Questionnaires that patients can use to assess skin toxicities related to treatment may help identify the intermediate-and long-term effects of cetuximab, panitumumab, or erlotinib hydrochloride. PURPOSE: This trial studies the validation of a cancer questionnaire for skin toxicities in patients with colorectal or lung cancer receiving cetuximab, panitumumab, or erlotinib hydrochloride.

Conditions Studied

Lung Cancer Colorectal Cancer Dermatologic Complications Therapy-related Toxicity

Interventions

  • PROCEDURE quality-of-life assessment
  • PROCEDURE psychosocial assessment and care
  • PROCEDURE assessment of therapy complications

Study Locations (20)

California

  • East Bay Radiation Oncology Center - Castro Valley
  • City of Hope Comprehensive Cancer Center - Duarte
  • Epic Care-Dublin - Dublin
  • Bay Area Breast Surgeons Inc - Emeryville
  • Epic Care Partners in Cancer Care - Emeryville
  • UC San Diego Moores Cancer Center - La Jolla
  • Loma Linda University Medical Center - Loma Linda
  • Los Angeles County-USC Medical Center - Los Angeles
  • USC / Norris Comprehensive Cancer Center - Los Angeles
  • Contra Costa Regional Medical Center - Martinez
  • El Camino Hospital - Mountain View
  • Highland General Hospital - Oakland
  • Alta Bates Summit Medical Center - Summit Campus - Oakland
  • Bay Area Tumor Institute - Oakland
  • Hematology and Oncology Associates-Oakland - Oakland
  • Doctors Medical Center- JC Robinson Regional Cancer Center - San Pablo

Arizona

  • University of Arizona Cancer Center-North Campus - Tucson
  • The University of Arizona Medical Center-University Campus - Tucson

Illinois

  • Saint Joseph Medical Center - Bloomington
  • Illinois CancerCare-Bloomington - Bloomington

Trial Details

FieldValue
Enrollment Target 146 participants
Start Date 2011-11-15
Est. Completion 2019-04-08

Sponsor

SWOG Cancer Research Network

270 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01416688

The ClinicalTrials.gov registry entry for NCT01416688 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (84% lower). The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which quality-of-life assessment is the first listed.

NCT01416688 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Illinois.

Frequently Asked Questions

What is clinical trial NCT01416688 about?

NCT01416688 is a clinical study titled "S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride". RATIONALE: Questionnaires that patients can use to assess skin toxicities related to treatment may help identify the intermediate-and long-term effects of cetuximab, panitumumab, or erlotinib hydrochloride. PURPOSE: This trial studies the validation of a cancer questionnaire for skin toxicities in ...

What is the current status of trial NCT01416688?

This trial is currently completed. The enrollment target is 146 participants. The study started on 2011-11-15. Estimated completion is 2019-04-08.

What conditions does trial NCT01416688 study?

This clinical trial studies the following conditions: Lung Cancer, Colorectal Cancer, Dermatologic Complications, Therapy-related Toxicity.

What interventions are being tested in trial NCT01416688?

The interventions under investigation include: quality-of-life assessment (PROCEDURE), psychosocial assessment and care (PROCEDURE), assessment of therapy complications (PROCEDURE).

Who is sponsoring clinical trial NCT01416688?

This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01416688 being conducted?

This trial has 20 study locations across Arizona, California, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer

All registered trials for this condition

Colorectal Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.